Influenza A virus H5N1 subtype - Pipeline Insight, 2021
This report can be delivered to the clients within 48 Hours
DelveInsight’s, “Influenza A virus H5N1 subtype – Pipeline Insight, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Influenza A virus H5N1 subtype pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Influenza A virus H5N1 subtype: Overview
H5N1 is called avian influenza or bird flu that causes a highly infectious, severe respiratory disease in birds. H5N1 is hard to transmit form people to people. But, the mortality of people infected by H5N1 is about 60%. In general, humans who catch a humanized influenza A virus (a human flu virus of type A) usually have symptoms that include fever, cough, sore throat, muscle aches, conjunctivitis, and, in severe cases, breathing problems and pneumonia that may be fatal. There are several H5N1 vaccines for several of the avian H5N1 varieties, but the continual mutation of H5N1 renders them of limited use to date: while vaccines can sometimes provide cross-protection against related flu strains, the best protection would be from a vaccine specifically produced for any future pandemic flu virus strain.
'Influenza A virus H5N1 subtype - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Influenza A virus H5N1 subtype pipeline landscape is provided which includes the disease overview and Influenza A virus H5N1 subtype treatment guidelines. The assessment part of the report embraces, in depth Influenza A virus H5N1 subtype commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Influenza A virus H5N1 subtype collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Influenza A virus H5N1 subtype report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Influenza A virus H5N1 subtype Emerging Drugs
Further product details are provided in the report
Influenza A virus H5N1 subtype: Therapeutic Assessment
This segment of the report provides insights about the different Influenza A virus H5N1 subtype drugs segregated based on following parameters that define the scope of the report, such as:
Influenza A virus H5N1 subtype: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Influenza A virus H5N1 subtype therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Influenza A virus H5N1 subtype drugs.
Influenza A virus H5N1 subtype Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Influenza A virus H5N1 subtype – Pipeline Insight, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Influenza A virus H5N1 subtype pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Influenza A virus H5N1 subtype: Overview
H5N1 is called avian influenza or bird flu that causes a highly infectious, severe respiratory disease in birds. H5N1 is hard to transmit form people to people. But, the mortality of people infected by H5N1 is about 60%. In general, humans who catch a humanized influenza A virus (a human flu virus of type A) usually have symptoms that include fever, cough, sore throat, muscle aches, conjunctivitis, and, in severe cases, breathing problems and pneumonia that may be fatal. There are several H5N1 vaccines for several of the avian H5N1 varieties, but the continual mutation of H5N1 renders them of limited use to date: while vaccines can sometimes provide cross-protection against related flu strains, the best protection would be from a vaccine specifically produced for any future pandemic flu virus strain.
'Influenza A virus H5N1 subtype - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Influenza A virus H5N1 subtype pipeline landscape is provided which includes the disease overview and Influenza A virus H5N1 subtype treatment guidelines. The assessment part of the report embraces, in depth Influenza A virus H5N1 subtype commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Influenza A virus H5N1 subtype collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Influenza A virus H5N1 subtype R&D. The therapies under development are focused on novel approaches to treat/improve Influenza A virus H5N1 subtype.
This segment of the Influenza A virus H5N1 subtype report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Influenza A virus H5N1 subtype Emerging Drugs
- NasoVAX: Altimmune
- Panblok: Protein science corporation
Further product details are provided in the report
Influenza A virus H5N1 subtype: Therapeutic Assessment
This segment of the report provides insights about the different Influenza A virus H5N1 subtype drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Influenza A virus H5N1 subtype
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Influenza A virus H5N1 subtype: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Influenza A virus H5N1 subtype therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Influenza A virus H5N1 subtype drugs.
Influenza A virus H5N1 subtype Report Insights
- Influenza A virus H5N1 subtype Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Influenza A virus H5N1 subtype drugs?
- How many Influenza A virus H5N1 subtype drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Influenza A virus H5N1 subtype?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Influenza A virus H5N1 subtype therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Influenza A virus H5N1 subtype and their status?
- What are the key designations that have been granted to the emerging drugs?
Introduction
Executive Summary
Influenza A virus H5N1 subtype: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Influenza A virus H5N1 subtype – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Influenza A virus H5N1 subtype companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Influenza A virus H5N1 subtype Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Mid Stage Products (Phase II)
Comparative Analysis
NasoVAX: Altimmune
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Preclinical stage products
Comparative Analysis
Ifenprodil - Algernon Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Influenza A virus H5N1 subtype Key Companies
Influenza A virus H5N1 subtype Key Products
Influenza A virus H5N1 subtype- Unmet Needs
Influenza A virus H5N1 subtype- Market Drivers and Barriers
Influenza A virus H5N1 subtype- Future Perspectives and Conclusion
Influenza A virus H5N1 subtype Analyst Views
Influenza A virus H5N1 subtype Key Companies
Appendix
Executive Summary
Influenza A virus H5N1 subtype: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Influenza A virus H5N1 subtype – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Influenza A virus H5N1 subtype companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Influenza A virus H5N1 subtype Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Mid Stage Products (Phase II)
Comparative Analysis
NasoVAX: Altimmune
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Preclinical stage products
Comparative Analysis
Ifenprodil - Algernon Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Influenza A virus H5N1 subtype Key Companies
Influenza A virus H5N1 subtype Key Products
Influenza A virus H5N1 subtype- Unmet Needs
Influenza A virus H5N1 subtype- Market Drivers and Barriers
Influenza A virus H5N1 subtype- Future Perspectives and Conclusion
Influenza A virus H5N1 subtype Analyst Views
Influenza A virus H5N1 subtype Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Influenza A virus H5N1 subtype
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Influenza A virus H5N1 subtype
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Influenza A virus H5N1 subtype
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Influenza A virus H5N1 subtype
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products